ABSTRACT: Introduction: Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary disorder that causes progressive muscle wasting. This study evaluates the use of proton magnetic resonance spectroscopy ( Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscle disease with an estimated prevalence of 3.96 per 100,000.
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscle disease with an estimated prevalence of 3.96 per 100,000. 1 Great progress has been made in elucidating the genetic and epigenetic mechanisms of disease in FSHD in recent years. 2 However, the ability to translate basic scientific discoveries into treatment is limited by the absence of quantitative biomarkers of muscle disease. 3 Recent studies have suggested that magnetic resonance spectroscopy (MRS) can differentiate between diseased and healthy muscle in FSHD. 4, 5 These studies used phosphorus-based MRS protocols, which identify metabolites involved in energy consumption in muscle. Proton ( 1 H) spectroscopy can also detect multiple metabolites in muscle, including creatine (Cr), trimethylamines (TMA), extramyocellular lipids (EMCL), and intramyocellular lipids (IMCL). These metabolites could be particularly relevant to the muscular dystrophies; muscle replacement by fat is a feature common to all muscular dystrophies, and Cr serves as a key substrate for energy metabolism in muscle. 6 In brain spectroscopy, the TMA peak comprises choline-containing compounds, including phospholipids that are implicated in cell membrane metabolism. 7 Studies in muscle also indicate that the TMA peak comprises several molecules involved in muscle metabolism, including carnitine and acetylcarnitine. 8 To evaluate the use of 1 H spectroscopy as a biomarker of muscle strength and function, we performed a cross-sectional study of multivoxel 1 H MRS in individuals with FSHD and in healthy volunteers.
MATERIALS AND METHODS
Study Design and Setting. The study protocol was approved by the Johns Hopkins Medicine Institutional Review Board. Individuals with genetically-confirmed FSHD and healthy adults (older than 18 years) provided written consent to participate in a single-center, cross-sectional study. Participants with FSHD were asked to provide copies of their genetic testing results. Participants with a clinical diagnosis of FSHD were asked to undergo confirmatory genetic testing for FSHD if it had not been performed prior to participation. Healthy volunteers were asked to undergo genetic testing for FSHD to confirm the absence of disease. Each potential participant was screened for contraindications to MRI scanning. Participants with FSHD were asked to return for an optional second scan between 18 and 24 months after the initial scan. All participants were enrolled and scanned between April 16, 2012 and January 30, 2015.
Additional supporting information may be found online in the Supporting Information section at the end of the article. 3 The echo signal was digitized with 512 data points and a spectral width of 2,000 HZ. Multivoxel MRS of the unsuppressed water signal was also acquired (scan parameters: TR/TE 1,800/30 ms; matrix size 16 3 16; slice thickness 1 cm; FOV 16 3 16 cm; total data acquisition time approximately 4:35 minutes). Shimming and water suppression were optimized by using automated routines provided by the manufacturer. Spectroscopy data were processed in LCModel software (LCMODEL Inc, Oakville, Ontario, Canada) with the vendor-provided basis set for muscle spectra. 9 Metabolite concentrations were estimated relative to the unsuppressed water signal (in institutional units [IU] ), and ratios with respect to Cr were also calculated. 10 The T1-weighted images of the slice used to place voxels for the MRS protocol were examined to exclude (1) voxels that were not entirely embedded in muscle and (2) intramuscular voxels that were infiltrated by fat. Voxels completely enclosed within the vastus lateralis, vastus medialis, rectus femoris, vastus intermedius, adductor magnus, sartorius, gracilis, long and short heads of the biceps femoris, semitendinosus, and semimembranosus muscles were selected for analysis (Supp. Info. Fig. 1 ). Because of the location and tissue composition of the voxel, coil placement limits, and other technical difficulties, spectral quality did not meet processing requirements in some collections. Spectra were excluded when they contained excessive noise or did not demonstrate identifiable metabolic peaks.
Abbreviations
Statistical Analysis. The distribution of metabolite concentrations was explored and examined for outliers by using histograms and box plots. Excessively right-skewed data were log transformed, and q-q plots were used to confirm the normal distribution of the resultant data. Multilevel mixed-effects linear regression models were used to assess differences in metabolite concentrations (the response variable) with respect to disease status (the independent variable). Because metabolite concentrations were expected to cluster within individual muscles and within participants, random effects parameters were included in the models to adjust for voxels nested within muscles that were nested within an individual and to generate accurate P-values. Muscle metabolite concentrations in the quadriceps muscle group (vastus lateralis, vastus medialis, vastus intermedius, and rectus femoris) and the hamstrings group (semitendinosus, semimembranosus, long head of the biceps femoris, and short head of the biceps femoris) were also examined with respect to measured strength in those muscle groups and the 10-meter walk times. Age, sex, and deletion size were explored as potential confounders in these multilevel models.
For the subset of participants who returned for followup scans, acquisition and analysis of spectra were performed by using the same protocol as the baseline scan. The metabolite concentrations from the baseline and follow-up scans were compared by using 2 methods. First, the mean concentration of each metabolite was calculated for each muscle for which data were available. The difference in the mean concentration between the baseline and follow-up scans was analyzed by using histograms, t tests, and Bland-Altman plots. Second, multilevel linear regression models were used to study the changes in concentration of each metabolite with respect to time (again grouped by individual participant and muscle). Data analysis was performed in the Stata 12/IC statistical software package (StataCorp, College Station, Texas).
RESULTS

Cross-Sectional Data Comparing Individuals With
FSHD and Controls. In total, 52 individuals participated in the observational study (36 with clinical diagnoses of FSHD and 16 healthy controls). One control was found to have somatic mosaicism for the FSHD mutation and was excluded from the analysis. The demographic features of the affected and unaffected participants as well as strength measurements in various muscle groups (values from the right and left sides are averaged) are summarized in Table 1 . Genetic testing results from participants with FSHD showed a broad range of chromosome 4 deletion sizes (restriction fragment sizes range from 10 to 33 kb).
1 H MRS was completed on both thighs for most participants (3 participants had only 1 leg studied). Spectra were collected from 256 individual voxels in each leg. Screening for voxels that were completely enclosed with muscle excluded 78% of all voxels, and screening for spectral fit excluded an additional 13% of the acquired voxels. Preliminary examination of the fat and water spectroscopy imaging indicated that there was insufficient field homogeneity in the majority of studies performed in the right lower extremity; therefore, only spectra and strength measurements from the left lower extremity were included in the analysis. Statistical analysis included 1,165 voxels (representing 32 individuals with FSHD and 14 controls). No usable voxels were identified in 5 individuals (4 with FSHD and 1 control), and the remaining participants contributed between 7 and 38 voxels to the data set. These voxels represent 11 individual muscles of the thigh (Supp. Info Fig. 1) .
The most commonly identified metabolite peaks included TMA at 3.2 ppm, Cr at 3.0 ppm, EMCL at 1.5 ppm, and IMCL at 1.3 ppm (Fig. 1) . Multilevel regression models demonstrated a statistically significant difference in TMA/Cr ratio between affected and unaffected participants (P 5 0.001; Fig. 2) . No statistically significant differences were identified in the concentrations of Cr, TMA, IMCL, and EMCL or the ratios of IMCL and EMCL to Cr (Table 2) . Age, sex, and deletion size were evaluated as potential confounders and were not found to modify the associations between disease status and metabolite concentrations; these factors were therefore not included in the final regression models.
Comparison of Metabolite Concentration and Clinical
Measurements in FSHD. The concentrations of Cr, TMA, IMCL, and EMCL of voxels located in the quadriceps (vastus lateralis, vastus medialis, vastus intermedius, and rectus femoris muscles) and hamstrings (semitendinosus, semimembranosus, long and short heads of the biceps femoris muscles) were averaged for each participant with FSHD. These muscle group concentration means were then compared with muscle strength in these respective muscle groups. Only TMA/Cr showed a moderately strong linear correlation with strength in the hamstrings, which was consistent with the cross-sectional analysis, indicating that muscle strength increases with increasing log[TMA/Cr] (r 5 0.62, P 5 0.0002). There was a weaker correlation between TMA/Cr concentration and the 10-meter walk time, but higher log[TMA/Cr] values were associated with a decrease in the 10-meter walk time (r 5 20.41, P 5 0.026; Fig. 3 ). No statistically significant association between strength or function and log[TMA/Cr] was seen in the quadriceps, which had a much narrower range of strength measurements. No significant association with muscle strength was observed in any of the other metabolites studied.
Longitudinal Data Analysis. Longitudinal spectroscopy data were obtained from 10 participants with FSHD between 18 and 24 months after the baseline scan. There were no statistically significant differences in knee flexion and knee extension strength between the baseline and follow-up scans. Neither the exploratory analysis nor the multilevel linear regression models showed a significant change in concentration from baseline to followup for any of the metabolites analyzed.
DISCUSSION
This study demonstrates that multivoxel proton MRS can detect metabolic abnormalities in the muscles of individuals with FSHD, even among voxels that contain no visible fat infiltration on T1-weighted imaging. When individuals with FSHD are compared with unaffected controls, there is a statistically significant reduction in the TMA/Cr ratio. These findings are similar to a prior study which also identified a decreased TMA/Cr ratio in individuals with Duchenne muscular dystrophy (DMD) versus controls. 6 However, that prior DMD study also found statistically significant differences in the TMA/water and Cr/water ratios, which were not found in the current FSHD study.
Examination of the TMA and Cr data suggests that the difference in TMA/Cr is driven primarily by the difference in TMA concentration, which is reduced in affected individuals compared with controls. Although the TMA concentration did not differ significantly between cases and controls, this may be a result of the large variability in concentration found for this particular metabolite. The mechanisms by which TMA and Cr concentrations may be altered in the early stages of FSHD are as yet unknown. However, given our knowledge of the composition of the TMA peak in brain and muscle, the relative reduction in TMA/Cr in affected muscles may reflect early muscle degeneration resulting in loss of muscle membrane and mitochondrial components. Additional studies on the pathophysiologic changes that occur early in skeletal muscle in individuals with FSHD are required to elucidate these mechanisms.
This study has some limitations. Although the multivoxel technique was successful in collecting data from multiple voxels in multiple muscle groups in a single acquisition, a large percentage of voxels could not be included in the analysis because they were not completely enclosed in normal-appearing muscle or had insufficient spectral fit. An examination of outliers also demonstrated marked differences in metabolite concentrations in the posterolateral aspect of the right lower extremity compared with the left lower extremity. This may be related to isolated scannerspecific field inhomogeneities. To compensate for this potential confounder, only the left lower extremity was analyzed for each participant, and this reduction in data may have reduced the power to detect changes in metabolite concentrations.
This study analyzed only the metabolic profiles of voxels consisting entirely of muscle without visible fat infiltration. Because fat infiltration is one of the primarily pathologic features of muscular dystrophy, the metabolic profiling of the fat-infiltrated voxels is also of interest as a biomarker, and prior studies have demonstrated changes in the intramuscular lipid concentration in muscular dystrophy by using spectroscopy. 11, 12 However, inspection of the individual spectra raised concerns regarding the inclusion of fat-infiltrated voxels in our analysis. Because intramuscular lipids comprise multiple molecules, multiple lipid peaks were also observed in the resultant spectra, some of which overlapped the range of the Cr and TMA signals. Because metabolites were subsequently scaled to Cr, we believed that the presence of these additional large lipid peaks could confound the quantification of those metabolites. By restricting our analysis to voxels without fat infiltration, we were able to investigate potential early differences in metabolic profiling that precede fat infiltration in FSHD.
We also did not collect data on several factors that may influence MRS, including exercise levels and medications. Global function scales that are specific to FSHD are also increasingly being used in clinical studies in FSHD and may provide greater insight into the associations between imaging and clinical function in this disease population. 13, 14 Fluid sensitive MRI sequences (such T2-weighted or short-tau inversion recovery [STIR] images) also were not included in the study protocol. T2 or STIR hyperintensity indicates the presence of edema or free water and is associated with active inflammation seen in affected muscles in individuals with FSHD. Because T2 values can influence spectroscopy measurements, future investigations should consider incorporating these fluid sensitive sequences. The relative utility of MRS as a biomarker could be even further defined by studying these scans in conjunction with other quantitative MRI sequences that have been studied as potential biomarkers in muscular dystrophy, such as Dixon estimation of muscle fat fractions and T2 mapping. [15] [16] [17] This study protocol also did not include repeatability and reliability testing (in part because of time constraints). Although prior studies have demonstrated acceptable repeatability and reliability for multiple spectroscopic techniques, [18] [19] [20] the application of a multivoxel MRS to future multicenter observational studies and clinical trials will require additional internal validation of both repeatability and reliability.
In the 18-24-month longitudinal data that were collected, no statistically significant changes in metabolite concentration over time were found. This observation differs from prior MRS data from patients with DMD that showed a time-dependent change in fat and water concentrations. 21 However, this difference may be related to the fact that only voxels corresponding to normal-appearing muscles on T1-weighted imaging were included in the current analysis. Doing so would necessarily exclude voxels that had been replaced by fat in between the baseline and follow-up scans. It is also possible that changes in spectroscopy are detectable over shorter periods of time in DMD because of the more rapid progression of disease compared with FSHD. Additional study is required to characterize fully the longitudinal changes in metabolite profiles in FSHD.
In conclusion, this study demonstrates that the TMA/Cr ratio in skeletal muscle of individuals with FSHD differs significantly from those of unaffected controls. This difference was found in normal-appearing muscle, suggesting that it is an early pathological change. There is also evidence that differences in the TMA/Cr ratio are associated with muscle strength. Additional study is required to determine the ways in which TMA/Cr levels change over time and whether these changes are predictive of deterioration of muscle function in muscular dystrophy.
